DE602007006663D1 - Verfahren zur behandlung von krebs - Google Patents

Verfahren zur behandlung von krebs

Info

Publication number
DE602007006663D1
DE602007006663D1 DE602007006663T DE602007006663T DE602007006663D1 DE 602007006663 D1 DE602007006663 D1 DE 602007006663D1 DE 602007006663 T DE602007006663 T DE 602007006663T DE 602007006663 T DE602007006663 T DE 602007006663T DE 602007006663 D1 DE602007006663 D1 DE 602007006663D1
Authority
DE
Germany
Prior art keywords
cancer
mammal
treatment
oleandomycin
tylosin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007006663T
Other languages
German (de)
English (en)
Inventor
Rina Rosin-Arbesfeld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of DE602007006663D1 publication Critical patent/DE602007006663D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DE602007006663T 2006-06-12 2007-06-12 Verfahren zur behandlung von krebs Active DE602007006663D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81260506P 2006-06-12 2006-06-12
PCT/IL2007/000706 WO2007144876A1 (en) 2006-06-12 2007-06-12 Methods for treating cancer

Publications (1)

Publication Number Publication Date
DE602007006663D1 true DE602007006663D1 (de) 2010-07-01

Family

ID=38541966

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007006663T Active DE602007006663D1 (de) 2006-06-12 2007-06-12 Verfahren zur behandlung von krebs

Country Status (7)

Country Link
US (1) US9486467B2 (https=)
EP (1) EP2029147B1 (https=)
JP (1) JP2009539970A (https=)
CN (1) CN101568343A (https=)
AT (1) ATE468119T1 (https=)
DE (1) DE602007006663D1 (https=)
WO (1) WO2007144876A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2894992A1 (en) 2012-12-24 2014-07-03 Ramot At Tel-Aviv University Ltd. Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same
WO2015198329A1 (en) 2014-06-25 2015-12-30 Bio Blast Pharma Ltd. Injectable formulations for intrathecal administration of antibiotic agents
US10919927B2 (en) 2017-02-22 2021-02-16 ISR Immune System Regulation Holding AB (publ) Immune stimulating macrolide
RU2746047C1 (ru) * 2017-04-06 2021-04-06 Шенянг Фуянг Фармасьютекал Технолоджи Ко., Лтд. Применение карримицина и его фармацевтически приемлемой соли для производства медикаментов для лечения и/или профилактики опухоли
RU2766176C2 (ru) * 2017-07-04 2022-02-08 Шенянг Фуянг Фармасьютекал Технолоджи Ко., Лтд. Применение изовалерил-спирамицина i, ii и/или iii при изготовлении препарата для лечения и/или профилактики опухоли и получения лекарственного препарата
CN110051845A (zh) * 2018-01-19 2019-07-26 沈阳福洋医药科技有限公司 一种mTOR抑制剂、药物组合物及其应用
MX2020007627A (es) 2018-01-19 2020-11-24 Shenyang Fuyang Pharmaceutical Tech Co Ltd Uso de la carrimicina o de sus ingredientes activos.
US11351185B2 (en) 2020-03-11 2022-06-07 Asclea Corporation Use of isovalerylspiramycins as anti-cancer agents to inhibit metastasis
WO2023283427A2 (en) * 2021-07-09 2023-01-12 Verdure Biotech, Inc. Enteric and delayed release formulations of locally bioavailable drugs (lbd) targeting the colon
WO2023114231A1 (en) * 2021-12-14 2023-06-22 The Regents Of The University Of California Clustered mutations for the treatment of cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4092473A (en) 1975-08-01 1978-05-30 Sanraku Ocean Co., Ltd. Tylosin derivatives and their manufacturing process
GB1540397A (en) 1976-12-08 1979-02-14 May & Baker Ltd Spiramycin esters
US4064143A (en) 1976-12-10 1977-12-20 Pfizer Inc. Oleandomycin derivatives
US4205163A (en) 1977-11-08 1980-05-27 Sanraku-Ocean Co., Ltd. Tylosin derivatives
US4124755A (en) 1978-01-03 1978-11-07 Pfizer Inc. 11-Alkanoyl-4"-deoxy-4"-isonitrilo-oleandomycin derivatives
SE445739B (sv) 1978-09-14 1986-07-14 Toyo Jozo Kk 3", 4"-diacyltylosinderivat
US4429116A (en) 1982-12-27 1984-01-31 Pfizer Inc. Alkylated oleandomycin containing compounds
US5872103A (en) * 1986-11-26 1999-02-16 Belletti; Dino A. Prevention of mammary tumors by treatment with cardiac glycosides
US5324720A (en) 1992-03-20 1994-06-28 Merck & Co., Inc. Methods of achieving antitumor activity using 16-membered-macrolide-type compounds
CA2127578A1 (en) 1993-07-08 1995-01-09 Keiichi Ajito 16-membered macrolide derivatives and process for producing the same
IL127946A0 (en) * 1996-07-08 2000-02-17 Cird Galderma Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents
AP1060A (en) 1998-01-02 2002-04-23 Pfizer Prod Inc Novel erythromycin derivatives.
HRP980646B1 (en) 1998-12-30 2008-02-29 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. Novel oleandomycin derivatives
IL133077A0 (en) * 1999-01-29 2001-03-19 Pfizer Prod Inc Azithromycin combination for emesis control in dogs
EA200100983A1 (ru) 1999-05-24 2002-10-31 Пфайзер Продактс Инк. Производные 13-метилэритромицина
US6455680B1 (en) 2000-12-21 2002-09-24 Abbott Laboratories Methods utilizing aryl thioimines in synthesis of erythromycin derivatives
US20050171032A1 (en) 2002-04-11 2005-08-04 Children's Medical Center Corporation Methods for the treatment of cancer
CN1562066A (zh) 2004-04-14 2005-01-12 山东鲁抗舍里乐药业有限公司 酒石酸泰乐菌素颗粒剂及其制备方法
GB0417852D0 (en) * 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products

Also Published As

Publication number Publication date
WO2007144876A1 (en) 2007-12-21
ATE468119T1 (de) 2010-06-15
EP2029147A1 (en) 2009-03-04
JP2009539970A (ja) 2009-11-19
US20110306571A1 (en) 2011-12-15
EP2029147B1 (en) 2010-05-19
US9486467B2 (en) 2016-11-08
CN101568343A (zh) 2009-10-28

Similar Documents

Publication Publication Date Title
DE602007006663D1 (de) Verfahren zur behandlung von krebs
CY1119140T1 (el) Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους
BRPI0720546A2 (pt) Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto
BRPI0715845A2 (pt) Composição farmacêutica para tratamento do câncer de pulmão, método de inibição do crescimento ou invasão do câncer de pulmão e método de tratamento do câncer de pulmão
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
BR112016011949A2 (pt) Composto, composição farmacêutica, e, uso dos mesmos”
PL374191A1 (en) 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
EP2132240A4 (en) COMPOSITIONS AND METHOD FOR TREATING A WATER BLOCKED DRILL OXIDE
PT1286671E (pt) Composicoes para o tratamento de cancro colorrectalque compreendem talidomida e irinotecan
MX2009012155A (es) Combinación farmacéutica sinérgica para el tratamiento de cáncer.
EP2140103A4 (en) COMPOSITIONS AND METHOD FOR TREATING A WATER BLOCKED BOREOLE
WO2008024977A3 (en) Isoquinoline, quinazoline and phthalazine derivatives
BRPI0921687A2 (pt) Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero.
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
ATE433980T1 (de) Gyraseinhibitoren und deren verwendungen
EA201000383A1 (ru) Способ ингибирования клостридиум диффициле введением оритаванцина
UA102128C2 (en) Nalmefene hydrochloride dihydrate
BRPI0913300A2 (pt) composto, processo para o preparo e uso do mesmo, método de tratamento de infecção bacteriana em um animal, e, composição farmacêutica.
WO2007149782A3 (en) Selective inhibitors for transferases
BRPI0812473A2 (pt) Composto, composição farmacêutica, métodos para inibir dna girase bacteriana e/ou topoisomerase iv bacteriana em um animal de sangue quente em necessidade de tal tratamento, para produzir um efeito antibacteriano em um animal de sangue quente em necessidade de tal tratamento, e para tratar uma infecção bacteriana em um animal de sangue quente em necessidade do mesmo, uso de um composto, e, processo para preparar um composto
EP2056840A4 (en) COMPOSITIONS, DEVICES AND METHODS OF TREATING MORBUS HUNTINGTON BY INTRA-CRANICAL LEVY FROM SIRNA
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
BRPI0920605A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para o tratamento ou profilaxia de infecção pelo hiv ou para o tratamento, profilaxia, ou retardo no início ou progressão da aids em um paciente em necessidade deste.
MX372951B (es) Composiciones y metodos de tratamiento que comprenden ceftarolina.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition